The Chart Confirming Cheapest Stocks In The Company
The Chart Confirming Cheapest Stocks In The Company History!
(push MAX on chart timeline)
https://www.barchart.com/stocks/quotes/KTN.VN/overview
At some point we will pass the previous record of 2,7 dollars IMO.
https://kootenaysilver.com/ - see catalysts for 2022 yet to unfold!
The board -
https://investorshangout.com/kootenay-silver-...231-94445/
Robert
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...
Continue Reading
Riding the Waves of Reform in China The winds of change are blowing through China's capital markets, and Guosen Securities is putting a stake in the ground with bold priorities for the 15th Five-Year Plan. As far as I'm concerned, the headlines here are thick with implications for anyone eyeing a piece of China's economic pie from 2026–2030. The Pillars of Stability and...
Continue Reading
CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...
Continue Reading
Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...
Continue Reading
Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...
Continue Reading
Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...
Continue Reading
Zinzino's Strategic Play in Europe's Wellness Market There's a new player on the European wellness block, and it's Zinzino's latest concoction of fermented botanical supplements. This isn't just your run-of-the-mill vitamin shop stock; we're talking about a lineup crafted for distinct parts of the day, reflecting an evolving consumer trend. People are looking for tailored...
Continue Reading
Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...
Continue Reading
Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...
Continue Reading
Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...
Continue Reading
Top 5 Most Recently Viewed Articles
DXC Technology Announces Upcoming Q3 Fiscal 2026 Earnings DXC Technology (NYSE: DXC), a prominent leader in enterprise technology and innovation, has set a date for the release of its financial results for the third quarter of fiscal 2026. The earnings report will be published on a Thursday, after the market closes, providing stakeholders with insights into the company's...
Continue Reading
Jim Cramer Recommends Mettler-Toledo International Inc. On a recent episode of CNBC's popular program, Jim Cramer advised investors to consider buying shares of Mettler-Toledo International Inc. (NYSE: MTD). Cramer's endorsement came after the company reported impressive quarterly results, showcasing strong financial health. Strong Earnings Report from Mettler-Toledo...
Continue Reading
Strategic Partnership Announced Leading cannabis companies Vireo Growth Inc. and Curio Wellness have forged a partnership aimed at leveraging shared resources to tap into the burgeoning cannabis market. This collaboration marks an exciting new chapter for both companies as they work to introduce innovative health and wellness products to consumers. Vireo Growth Inc.: A...
Continue Reading
Overview of the Interim Report for 2024 The interim report covering January to June 2024 provides important insights into Anoto Group AB's operations and financial health. Anoto Group continues to be a leader in technology, particularly in optical recognition and digital writing. This report emphasizes key financial metrics and the company's strategic initiatives in a...
Continue Reading
The Challenge of Orthobiologics: Hype vs. Science Amid the buzz around orthobiologics, it's high time folks face reality: enthusiasm doesn't equal evidence. Dr. Jason Dragoo, the symposium co-chair, hit the nail right on the head—the medical community's chief duty is to sift the wheat from the chaff when it comes to flashy new treatments that lack scientific backing....
Continue Reading